UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 357

Sortiert nach

Effects of KRAS, BRAF, NRAS , and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

The lancet oncology, 2010-08, Vol.11 (8), p.753-762

2010

Volltextzugriff (PDF)

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

The New England journal of medicine, 2019-10, Vol.381 (17), p.1632-1643

2019

Volltextzugriff (PDF)

Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review

BMC cancer, 2020-02, Vol.20 (1), p.105-105, Article 105

2020

Volltextzugriff (PDF)

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

Journal of clinical oncology, 2012-05, Vol.30 (15), p.1755-1762

2012

Volltextzugriff (PDF)

Chemotherapy or Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer?

Annals of surgery, 2015-05, Vol.261 (5), p.956-960

2015

Volltextzugriff (PDF)

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data

Cancers, 2021-03, Vol.13 (5), p.1031

2021

Volltextzugriff (PDF)

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort

PloS one, 2015-06, Vol.10 (6), p.e0131046-e0131046

2015

Volltextzugriff (PDF)

Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients

Journal of gastroenterology, 2019-02, Vol.54 (2), p.108-121

2019

Volltextzugriff (PDF)

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies

Cancers, 2023-12, Vol.16 (1), p.126

2023

Volltextzugriff (PDF)

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells

Nature communications, 2016-08, Vol.7 (1), p.12436-12436, Article 12436

2016

Volltextzugriff (PDF)

Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol

BMJ open, 2023-06, Vol.13 (6), p.e073372-e073372

2023

Volltextzugriff (PDF)

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

Frontiers in oncology, 2020-02, Vol.10, p.8-8

2020

Volltextzugriff (PDF)

Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis

Acta oncologica, 2020-04, Vol.59 (4), p.417-426

2020

Volltextzugriff (PDF)

Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials

Current oncology (Toronto), 2023-07, Vol.30 (7), p.6820-6837

2023

Volltextzugriff (PDF)

Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis

Therapeutic advances in medical oncology, 2018-01, Vol.10, p.1758835918777036-1758835918777036

2018

Volltextzugriff (PDF)

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study

BMC cancer, 2022-12, Vol.22 (1), p.1321-1321, Article 1321

2022

Volltextzugriff (PDF)

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer

PloS one, 2017-08, Vol.12 (8), p.e0182512-e0182512

2017

Volltextzugriff (PDF)

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

Oncotarget, 2016-11, Vol.7 (46), p.75013-75022

2016

Volltextzugriff (PDF)

Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients

Cancer, 2009-10, Vol.115 (20), p.4679-4687

2009

Volltextzugriff (PDF)

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

BMC cancer, 2023-06, Vol.23 (1), p.552-552, Article 552

2023

Volltextzugriff (PDF)

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359221146137-17588359221146137

2023

Volltextzugriff (PDF)

Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash

Supportive care in cancer, 2017-07, Vol.25 (7), p.2179-2185

2017

Volltextzugriff (PDF)

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan

PloS one, 2014-06, Vol.9 (6), p.e99886-e99886

2014

Volltextzugriff (PDF)

How to select cancer patients for immunotherapy

EBioMedicine, 2021-01, Vol.63, p.103184-103184, Article 103184

2021

Volltextzugriff (PDF)

Prediction of overall survival in patients with locally advanced pancreatic cancer using longitudinal diffusion-weighted MRI

Frontiers in oncology, 2024-07, Vol.14, p.1401464

2024

Volltextzugriff (PDF)

1 – 25 von 357

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(302)
Mit Volltextzugriff
(322)

Publikationsform

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(200)
Life Sciences & Biomedicine
(188)
Humans
(171)
Oncology
(154)
Female
(101)
Aged
(99)
Male
(92)
Middle Aged
(89)
Adult
(73)
Chemotherapy
(67)
Colorectal Cancer
(60)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(58)
Colorectal Neoplasms - Drug Therapy
(53)
Metastasis
(45)
Cancer
(42)
Prognosis
(42)
Aged, 80 And Over
(41)
Tumors
(41)
Treatment Outcome
(39)
Medicin Och Hälsovetenskap
(38)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

Effects of KRAS, BRAF, NRAS , and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Encorafenib, Binimetinib, and Cetuximab in BRAF V600E–Mutated Colorectal Cancer

Bidirectional treatment of peritoneal metastasis with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) and systemic chemotherapy: a systematic review

Phase III Trial of Cetuximab With Continuous or Intermittent Fluorouracil, Leucovorin, and Oxaliplatin (Nordic FLOX) Versus FLOX Alone in First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-VII Study

Chemotherapy or Liver Transplantation for Nonresectable Liver Metastases From Colorectal Cancer?

Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data

High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer Cohort

Tumor-specific genetic aberrations in cell-free DNA of gastroesophageal cancer patients

Treatment Options in Late-Line Colorectal Cancer: Lessons Learned from Recent Randomized Studies

miR-625-3p regulates oxaliplatin resistance by targeting MAP2K6-p38 signalling in human colorectal adenocarcinoma cells

Evaluating the efficacy and safety of neoadjuvant pembrolizumab in patients with stage I-III MMR-deficient colon cancer: a national, multicentre, prospective, single-arm, phase II study protocol

CDX2: A Prognostic Marker in Metastatic Colorectal Cancer Defining a Better BRAF Mutated and a Worse KRAS Mutated Subgroup

Molecular characterization of a large unselected cohort of metastatic colorectal cancers in relation to primary tumor location, rare metastatic sites and prognosis

Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma-A Critical Review of Randomised Trials

Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis

A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study

High RBM3 expression is associated with an improved survival and oxaliplatin response in patients with metastatic colorectal cancer

Interleukin-6 and C-reactive protein as prognostic biomarkers in metastatic colorectal cancer

Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients

A randomized phase II study of full dose gemcitabine versus reduced dose gemcitabine and nab-paclitaxel in vulnerable patients with non-resectable pancreatic cancer (DPCG-01)

Trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer: results of a systematic review and meta-analysis

Placebo-controlled phase II study of vitamin K3 cream for the treatment of cetuximab-induced rash

miR-345 in metastatic colorectal cancer: a non-invasive biomarker for clinical outcome in non-KRAS mutant patients treated with 3rd line cetuximab and irinotecan

How to select cancer patients for immunotherapy

Prediction of overall survival in patients with locally advanced pancreatic cancer using longitudinal diffusion-weighted MRI

Suchergebnisse filtern